Janssen / Johnson & Johnson

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). CRS and neurologic toxicity (damage to the nervous system which includes the brain, spinal cord, and nerves) are potential risks of treatment with talquetamab and teclistamab. CRS involves a release of a large amount of proteins into the bloodstream causing inflammation. This may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and/or affect the lung/liver/kidney function. It may also cause certain brain-related symptoms, such as dizziness, weakness, confusion, difficulty speaking, and/or decreased brain function (possible paralysis and/or coma). Infliximab is a drug that prevents the tumor necrosis factor-alpha (TNF-α) from working. TNF-α is a cytokine, or chemical messenger, that helps your immune system produce inflammation. Giving infliximab may work well for the prevention of cytokine release syndrome during treatment with teclistamab or talquetamab in patients with relapsed or refractory multiple myeloma.Show more

The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells \[WBCs\] called plasma cells) for whom stem cell transplant is not planned as initial therapy.Show more

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).Show more

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

The aim of this study is to assess the clinical efficacy of the anti-BCMA/CD3 bispecific antibody teclistamab and anti-GPRC5D/CD3 bispecific antibody talquetamab in a prospective, real-life setting in Belgium.

Janssen, the pharmaceutical division of Johnson & Johnson, works across several therapeutic areas, including rare neurological, blood and immune disorders. In April 2025, the FDA approved Imaavy (nipocalimab), an FcRn blocker, for generalized myasthenia gravis in patients 12 and older who are anti-AChR or anti-MuSK antibody positive. In August 2026, Imaavy became the first FDA-approved treatment for warm autoimmune hemolytic anemia, for patients 12 and older who are taking or have taken corticosteroids. Nipocalimab is also in trials for CIDP, Sjögren's disease and pregnancies at risk of hemolytic disease of the fetus and newborn.

Janssen / Johnson & Johnson has active programs across 15 rare diseases: Chronic Graft-versus-Host Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Dermatomyositis, Focal Epilepsy, Generalized Pustular Psoriasis, Geographic Atrophy, Lennox-Gastaut Syndrome, Light Chain Amyloidosis, Multiple Myeloma, Myasthenia Gravis, Myelodysplastic Syndromes, Pulmonary Arterial Hypertension, Sickle Cell Disease, Sjögren's Syndrome, Waldenström Macroglobulinemia. These span several therapeutic areas. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

Janssen / Johnson & Johnson is a diversified pharmaceutical company headquartered in New Brunswick, United States, founded in 1886. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 15 active rare disease programs including Chronic Graft-versus-Host Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Dermatomyositis. Many of its rare disease treatments hold orphan drug designations from the FDA.

The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Janssen / Johnson & Johnson, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

Janssen / Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, United States. The company has been active for 140 years. It trades publicly under the ticker symbol JNJ.